Prostamax

Also known as: KEDP, Lys-Glu-Asp-Pro, prostate tetrapeptide

3 notable studies · 2 references

View Supplier Listings Take This Prostamax Study With You

TLDR

Prostamax is the synthetic tetrapeptide Lys-Glu-Asp-Pro (KEDP), with limited laboratory evidence involving chromatin changes in cultured human lymphocytes and prostate-tissue growth in rat organ culture, but no established human administration evidence or controlled studies showing benefit for prostatitis, BPH, urinary symptoms, prostate size, or other prostate disease; clinical evidence involving the separate prostate extract Prostatilen should not be attributed to Prostamax.

 Research Supports Studied (as KEDP) for tissue-specific growth stimulation in rat prostate organ culture
Investigated for effects on heterochromatin organization in cultured human lymphocytes
Explored within a chromatin/gene-regulation aging framework
No established evidence exists for BPH, prostatitis, PSA, or urinary symptoms
 

 Observations Reported in Research In rat organotypic tissue culture, Prostamax reportedly stimulated growth/outgrowth specifically in prostate explants, while other peptides affected other organs
Cultured lymphocytes from older human donors showed changes in heterochromatin organization after KEDP exposure (2004 study; 2012 follow-up)
No published human administration study of Prostamax/KEDP was identified
Clinical evidence for the separate extract Prostatilen should not be attributed to Prostamax
 

These are brief summaries of what the referenced research examined or reported — not conclusions about safety or effectiveness, and not medical advice. See Notable Studies and Sources & References below for the full context and citations.

At a Glance

Classification: Synthetic tetrapeptide; short peptide bioregulator; experimental prostate-associated peptide

Prostamax is the defined tetrapeptide Lys-Glu-Asp-Pro (KEDP). It is marketed as the prostate-specific member of the Khavinson short-peptide family. Prostamax is not Prostatilen. Prostamax/KEDP is one synthetic four-amino-acid molecule. Prostatilen is a heterogeneous animal-prostate peptide extract with a separate clinical literature. Clinical studies of Prostatilen are frequently cited online as though they establish the effects of Prostamax. They do not. The direct evidence for KEDP itself is remarkably small. Human administration trials have not been established, and its prostate-specific evidence consists largely of experimental tissue/cellular work rather than studies of BPH, prostatitis, urinary symptoms or prostate disease.

What Is Prostamax?

Prostamax is Lys-Glu-Asp-Pro (KEDP). The compound was developed within the short-peptide bioregulator program and associated with prostate tissue. There is some experimental support for tissue specificity: an organotypic-culture experiment reportedly exposed tissues from young and old rats to several organ-associated peptides and found that each stimulated growth primarily in its corresponding tissue, including Prostamax in prostate explants. That is essentially the entire direct prostate-specific experimental foundation. No convincing direct KEDP study has established effects on prostate volume, PSA, urinary flow, benign prostatic hyperplasia, chronic prostatitis, prostate cancer, or human lower urinary tract symptoms.

What Are Researchers Studying?

Prostate tissue

A rat organotypic-tissue experiment compared several short peptides in tissue cultures. Prostamax reportedly stimulated development/outgrowth of prostate explants, while other peptides showed corresponding effects in heart, lung and pancreatic tissue. This provides direct evidence for a prostate association. It is still rat prostate tissue in culture, not treatment of prostate disease.

Chromatin organization

Several KEDP experiments involve cultured lymphocytes obtained from older human donors. Researchers reported changes in heterochromatin organization after exposing the cells to KEDP. These experiments are often incorporated into broad “anti-aging” explanations. But they did not examine prostate cells, prostate function, BPH, or prostatitis. Because the cells were treated in the laboratory, human lymphocytes are not human administration evidence.

Age-associated gene activity

The Khavinson model proposes that condensed chromatin during aging may suppress gene activity and that short peptides can alter this organization. KEDP has been investigated within that framework. However, chromatin decondensation is a mechanistic cellular observation—not automatically a beneficial anti-aging effect. Some chromosomal endpoints reported in this literature can also be examined as markers of genomic stress. Aminodex should not automatically label every increase in chromosomal activity as beneficial.

Prostatitis

This is one of the biggest evidence traps. There is Russian clinical literature involving Prostatilen, the animal-prostate peptide extract, including chronic-prostatitis research. That is not Prostamax evidence. No controlled Prostamax/KEDP human prostatitis study was identified.

Benign prostatic hyperplasia

Despite extensive commercial claims, no direct study establishing Prostamax in a BPH model was identified in the literature reviewed. There is no established evidence that KEDP shrinks prostate volume, reduces PSA, improves urinary flow, or reduces obstruction. BPH should probably appear under What we still don't know rather than as an established Research Area.

How Does It Work?

Unknown. The proposed bioregulator model is KEDP, then cellular uptake, then possible chromatin/gene-regulatory effects, then tissue-associated changes, then possible effects on prostate-cell function. Only pieces of that chain have experimental evidence. There is no established Prostamax receptor and no validated human pharmacodynamic mechanism.

What Does the Research Show?

Human research

Human administration: NONE ESTABLISHED. No published study was identified in which people were administered Prostamax/KEDP, and no registered Prostamax clinical trial was found in current evidence reviews. Human-derived cells: YES. Cultured lymphocytes from older human donors have been exposed to KEDP in vitro. Correct display: Human clinical evidence NONE; human-derived cellular evidence YES.

Animal research

This is thinner than its reputation suggests. There is direct rat organotypic prostate-tissue culture evidence, but that is technically ex vivo rather than an in-vivo prostate-disease experiment. Exact KEDP evidence should be classified as animal tissue/ex-vivo evidence VERY LIMITED rather than a generic animal-evidence checkmark.

In-vitro research

LIMITED. The most notable experiments involve human lymphocytes, chromatin organization, and cytogenetic endpoints. These are not prostate-disease experiments.

Notable Studies

The Influence of the Peptide Bioregulator Prostamax on Heterochromatin of Human Lymphocytes In Situ

in-vitro

2004

Cultured lymphocytes obtained from older human donors were exposed to Prostamax/KEDP, and investigators reported changes in heterochromatin organization.

Limitations: Human cells rather than human administration; lymphocytes rather than prostate tissue; chromatin changes do not establish prostate benefit, anti-aging effects or clinical efficacy.

View publication →

Deheterochromatinization of Chromatin in Old Age Induced by Oligopeptide Bioregulator Lys-Glu-Asp-Pro

in-vitro

2012

Investigators exposed lymphocytes from older donors to KEDP and reported decondensation of heterochromatin, interpreted within their model as reactivation of age-associated suppressed chromatin.

Limitations: Does not examine prostate cells or administer KEDP to humans. Whether the observed chromatin changes are beneficial, neutral or potentially adverse in vivo remains unknown.

View publication →

Tissue-specific organ-culture experiment

animal

Prostate, pancreatic, bronchial and cardiac tissues from young and old rats were cultured with corresponding short peptides. Prostamax reportedly stimulated growth/outgrowth in prostate tissue, providing the principal direct experimental support for its proposed tissue association.

Limitations: Rat tissue culture only; no prostate-disease model, no living-animal therapeutic outcome, no urinary or hormonal endpoint, and no human evidence. Original Russian citation should be verified in the CMS before publication rather than inventing a polished bibliographic entry from secondary indexing.

What We Still Don't Know

Almost everything clinically important: human pharmacokinetics; human bioavailability; half-life; tissue distribution; whether intact KEDP reaches the human prostate; primary molecular target; whether it affects prostate epithelial cells in vivo; whether it affects stromal cells; whether it affects PSA; whether it affects prostate volume; whether it affects BPH; whether it affects prostatitis; whether it changes urinary symptoms; whether it affects prostate cancer biology; whether it interacts with androgen signaling; human safety; genotoxicity; reproductive safety; long-term effects; independent replication.

Related Compounds

Take the Prostamax research with you.

Get the Aminodex Prostamax Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.

One-time email. We do not add you to any mailing list.

Sources & References

Supplier Listings

A directory of relevant research suppliers for this compound is not yet available.